Table 1.
Demographic and clinical characteristics of cases and controls.
| Variable | HCC N=249 | CHC-only N=462 | P |
|---|---|---|---|
| Male, N (%) | 114 (45.8) | 219 (47.4) | 0.680 |
| Age (years) | 62.00 (58.00, 67.00) | 59.00 (54.00, 66.00) | 0.003 |
| Diabetes, N (%) | 50 (20.1) | 77 (16.7) | 0.257 |
| Gallstone, N (%) | 69 (27.7) | 83 (18.0) | 0.002 |
| Liver cirrhosis, N (%) | 198 (79.5) | 85 (18.4) | <0.001 |
| PLT (109/L) | 90.00 (60.00, 131.50) | 131.50 (92.75, 176.00) | <0.001 |
| AST (IU/L) | 68.00 (39.60, 108.50) | 55.00 (33.00, 92.50) | 0.001 |
| ALT (IU/L) | 46.00 (28.40, 76.20) | 62.00 (30.00, 117.25) | 0.001 |
| GGT (IU/L) | 72.20 (37.40, 148.70) | 53.00 (25.00, 105.50) | <0.001 |
| ALP (IU/L) | 108.70 (79.00, 147.35) | 83.75 (67.00, 113.60) | <0.001 |
| TBiL (μmol/L) | 24.20 (17.45, 46.70) | 16.85 (12.10, 23.93) | <0.001 |
| ALB (g/L) | 32.80 (27.40, 37.85) | 37.60 (34.38, 40.80) | <0.001 |
| CHE (IU/L) | 3560.00 (2048.00, 5294.50) | 6464.50 (4463.75, 7827.75) | <0.001 |
| PT | 12.70 (11.50, 14.40) | 11.50 (10.70, 12.50) | <0.001 |
| AAR | 1.43 (1.05, 1.96) | 0.91 (0.69, 1.27) | <0.001 |
| APRI | 1.94 (0.94, 3.78) | 1.13 (0.56, 2.29) | <0.001 |
| FIB4 | 6.66 (4.06, 11.86) | 0.83 (0.56, 1.48) | <0.001 |
| GPR | 0.85 (0.38, 1.81) | 0.45 (0.20, 0.96) | <0.001 |
Continuous variables are expressed as median (25th, 75th percentiles). AST – aspartate aminotransferase; ALT – alanine aminotransferase; ALP – alkaline phosphatase; GGT – gamma-glutamyl transpeptidase; TBiL – total bilirubin; ALB – albumin; CHE – cholinesterase; PT – prothrombin time; HCC – hepatocellular carcinoma; CHC – chronic hepatitis C; PLT – platelet count; APRI – AST-to-PLT ratio index; GPR – GGT to PLT ratio; AAR – AST to ALT ratio; FIB-4 – fibrosis index based on four factors